Press release
Psoriasis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Psoriasis Disease Pipeline Drugs
Psoriasis is a genetic inflammatory diseases which affects skin. Psoriasis is charecterised by skin cells that multiply up to 10 times faster than normal. When these cells reach surface and die, raised, red plaques covered with white scales for. Psoriasis begins as a small scaling papule. When multiple papules coalesce, they form scaling plaques. These plaques tend to occur in the scalp, elbows, and knees.
Symptoms includes red patches on skin, small scaling spots, dry and cracked skin, burning, itching and soreness of skin, bleeding etc. Psoriasis is diagnosed by physical examination and skin biopsy. Psoriasis is treated by topical corticosteroids, Vitamin D analogues,Topical retinoids, Calcineurin inhibitors etc. and it can be treated by phototherapy
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
By Trial Phase, Psoriasis pipeline drugs are segmented as:
• Preclinical Trials
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Psoriasis pipeline drugs are segmented as:
• Galderma
• Arcutis, Inc.
• Almirall, S.A.
• proDERM GmbH
• Novartis Pharmaceuticals
• GlaxoSmithKline
• AbbVie
• BoehringerIngelheim
• Others
By Drugs, Psoriasis pipeline drugs are segmented as:
• Icotinib Hydrochloride
• Bimekizumab
• Calcipotriene
• Ustekinumab
• Risankizumab
• Methotrexate
• Others
By Type of Condition, Psoriasis pipeline drugs are segmented as:
• Plaque psoriasis
• Scalp psoriasis
• Guttate psoriasis
• Nail psoriasis
• Inverse psoriasis
• Pustular psoriasis
• Erythrodermic psoriasis
• Psoriatic arthritis
By Route of Administration, Psoriasis pipeline drugs are segmented as:
• Oral
• Parenteral
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
• In November 2016,Janssen-Cilagsubmitted Marketing Authorisation Application to the European Medicines Agency (EMA) seeking approval of CNTO 1959 (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis
• In March 2016, Dr. Reddy’s Laboratories and XenoPort, Inc. entered into a license agreement pursuant to which Dr. Reddy’s Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort’s clinical-stage oral new chemical entity, XP23829. Dr. Reddy’s Laboratories plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis
Report Description:
Psoriasis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Psoriasis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Psoriasis disease pipeline drugs development. This report studies the dynamics of the Psoriasis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Psoriasis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on the each drug candidates in the clinical trial phases
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here
News-ID: 1040203 • Views: …
More Releases from Precision Business Insights
Gaming Controller Market Rising Demand for Gaming Stations and eSports
According to the Precision Business Insights (PBI), latest report the gaming controller market size was valued at USD 2,382.1 million in 2023, growing at an 8.5% CAGR from 2024 to 2030. The key drivers of the expansion of the global gaming controller include the enhanced gaming experience, technology advancements, consumer preferences and ergonomics, competitive gaming and esports, intuitiveness, and portability of the gaming controllers.
View Full Report: https://www.precisionbusinessinsights.com/market-reports/gaming-controller-market …
Next Generation Dietary Supplements Market Size, Growth Opportunities 2024-2030
According to Precision Business Insights (PBI), the latest report, the global next-generation dietary supplements market was valued at USD 10,752.3 million in 2023 and is expected to grow at a CAGR of 8.8% from 2024-2030. The primary factors that drive the market are the growing demand for rising consumer knowledge of the various health benefits of Next Generation Dietary Supplements, as well as rising disposable income levels, fuel market expansion…
Catamaran Market Increasing Popularity Of Water Sports And Fishing Activities
According to Precision Business Insights (PBI), the latest report, the catamaran market is valued at USD 1,635.7 million in 2023 and is anticipated to grow a CAGR of 4.9% over the forecast period. The primary factors that drive the market are the growing demand for Catamaran pushes the market to enhance efficiency, minimize time consumption, and reduce post-harvest operating losses. Catamaran are good solutions for reducing high labour costs since…
Refrigerated Display Cases Market Size, Share, Growth Trends and Forecast 2024-2 …
According to Precision Business Insights (PBI), latest report, the refrigerated display cases market was valued at USD 8,248.5 million in 2023 and is expected to grow at a 5.1% CAGR from 2024 to 2030. The primary drivers of the expansion of the global refrigerated display cases market include the increasing demand for frozen food and drinks among urban consumers. In addition, growing awareness about environment sustainability and energy efficiency is…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
